0000891839-20-000018.txt : 20200106
0000891839-20-000018.hdr.sgml : 20200106
20200106163442
ACCESSION NUMBER: 0000891839-20-000018
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191231
FILED AS OF DATE: 20200106
DATE AS OF CHANGE: 20200106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Van Strydonck, Gerald E.
CENTRAL INDEX KEY: 0001748247
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38624
FILM NUMBER: 20510193
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVENUE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VACCINEX, INC.
CENTRAL INDEX KEY: 0001205922
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 161603202
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
BUSINESS PHONE: 585-271-2700
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
FORMER COMPANY:
FORMER CONFORMED NAME: VACCINEX INC
DATE OF NAME CHANGE: 20021114
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-12-31
0001205922
VACCINEX, INC.
VCNX
0001748247
Van Strydonck, Gerald E.
C/O VACCINEX, INC.
1895 MOUNT HOPE AVENUE
ROCHESTER
NY
14620
1
0
0
0
Stock Option (Right to Buy)
10.00
2020-03-06
Common Stock
4500
4500
D
Stock Option (Right to Buy)
14.90
2023-03-06
Common Stock
7500
7500
D
Stock Option (Right to Buy)
13.60
2027-09-15
Common Stock
6396
6396
D
Stock Option (Right to Buy)
5.26
2029-03-30
Common Stock
2501
2501
D
Stock Option (Right to Buy)
7.78
2020-05-15
Common Stock
7718
7718
D
Stock Option (Right to Buy)
7.17
2019-09-30
2029-09-27
Common Stock
1856
1856
D
Stock Option (Right to Buy)
4.85
2019-12-31
4
A
0
2737
0
A
2019-12-31
2029-12-28
Common Stock
2737
2737
D
Exercisable in full as of the date of this report.
This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the fourth quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.
/s/ Scott E. Royer, Attorney-in-Fact for Gerald E. Van Strydonck
2020-01-06